425: ISS Recommends ACELYRIN Stockholders Vote For Proposed Merger with Alumis

Leading proxy advisory firm ISS recommends ACELYRIN stockholders vote in favor of the proposed merger with Alumis, citing potential upside and strategic rationale.

Summary

• ACELYRIN, INC. announced that ISS has recommended stockholders vote FOR the proposed merger with Alumis Inc.
• The special meeting of stockholders to vote on the Proposed Transaction is scheduled for May 13, 2025.
• ISS stated that a vote FOR the transaction is warranted due to uncertainties about alternatives, a premium to the unaffected price, and a logical strategic rationale.
• The ISS also noted uncertainties with liquidation, including potentially lower asset sales, a lengthy process, and associated costs.
• Guggenheim Securities, LLC is serving as financial advisor to ACELYRIN, and Fenwick & West LLP and Paul Hastings LLP are serving as legal counsel.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment, emphasizing the benefits of the merger and the ISS recommendation, but also acknowledges potential risks and uncertainties.

Positives

• ISS recommendation supports the merger, potentially influencing stockholder votes.
• The offer represents a premium to the unaffected price, providing immediate value to stockholders.
• The strategic rationale for the merger is considered logical by ISS.
• The merger is seen as a more certain path forward compared to alternatives like liquidation.

Negatives

• ISS acknowledges concerns with the offer value and potential conflicts of interest.
• Uncertainties exist regarding the availability and upside of potential alternatives.
• There are inherent uncertainties associated with a liquidation scenario.

Risks

• The Proposed Transaction may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be received.
• The announcement of the Proposed Transaction may negatively impact Alumis' or ACELYRIN's ability to retain key personnel and maintain relationships.
• The Proposed Transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the Proposed Transaction could arise.
• The anticipated benefits and synergies of the Proposed Transaction may not be fully realized.
• There are risks relating to the value of Alumis securities to be issued in the Proposed Transaction.
• Integration of the Proposed Transaction post-closing may not occur as anticipated.

Future Outlook

The combined company is expected to be stronger and more diversified, maximizing the potential of lonigutamab.

Management Comments

• We are pleased ISS recognizes that the merger with Alumis is the most certain path forward to maximize value for our stockholders.
• The ACELYRIN Board and management team are confident that the merger provides stockholders with significant potential upside as part of a stronger, more diversified combined company that is best positioned to maximize the potential of lonigutamab.

Industry Context

The announcement comes amid significant changes in the macroeconomic environment for biotech companies, influencing the assessment of potential alternatives and offer prices.

Comparison to Industry Standards

• The document references ISS, a leading independent proxy advisory firm, indicating adherence to corporate governance standards.
• The engagement of Guggenheim Securities and Fenwick & West LLP aligns with industry practice for mergers and acquisitions.

Stakeholder Impact

• Stockholders are urged to vote on the proposed merger, impacting the future of their investment.
• Employees of both ACELYRIN and Alumis may be affected by the integration of the two companies.
• The merger could impact the development and delivery of transformative medicines to patients.

Next Steps

• ACELYRIN urges its stockholders to vote FOR the Proposed Transaction.
• Stockholders will vote on the Proposed Transaction at the special meeting on May 13, 2025.

Key Dates

Keywords

merger, ACELYRIN, Alumis, stockholders, ISS, proxy advisory, transaction, lonigutamab, biopharma, immunology